CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
Kossel Medtech›
Library
Kossel Medtech

Kossel Medtech

Kossel Medtech develops coronary, peripheral, and electrophysiology interventional devices for hospitals and OEM partners.

Operating headquarters
Suzhou, Jiangsu, CN🇨🇳
Founded
2013
Loading
Overview
M & A
Compare
Employees
News
Library

Kossel Medtech - Library

kossel-medical.com·Crawled Oct 9, 2026·

Topics

Publication type

Content origin
Row density

Product

6 pages
  1. Bridflex® Steerable Introducer Sheath Kit/steerable-introducer-sheath-kit

    Bridflex® Steerable Introducer Sheath Kit A. Easily In PlaceAsymmetric bidirectional bend, one side is tilted 180 degrees and the other side is tilted 90 degrees for easy access to the target.The non-radiopaque head-end design allows for accurate positioning of the sheath under fluoroscopy. B. Strong SupportThe fully woven body provides excellent torque and support.The catheter […]

  2. Cardiac Ablation Catheter/cardiac-ablation-catheter

    Cardiac Ablation Catheter is designed for the mapping, recording and pacing of electrophysiological signals.

  3. Cathfree® Steerable Curve Diagnostic Catheter/steerable-curve-diagnostic-catheter

    Cathfree® Steerable Curve Diagnostic Catheter Previous Next A. Smooth Bending TransitionThe curve of bending steel wire is smooth, which makes operating in a narrow space safe B. Safe Head EndMaterial is Pebax and soft, non-knitted, which results in the safety of catheter operation C. Clear Signal PresentationHigh purity platinum-iridium alloy anodes record signals accurately and […]

  4. Cathrough™ Transseptal Needle and Sheath Kit/cathrough-transseptal-needle-and-sheath-kit

    Cathrough™ Transseptal Needle and Sheath Kit Cathrough™ Transseptal Needle and Sheath Kit  Product Feature Safe Puncture Rounded needle tip edge reduces friction with the dilator’s inner wall. Smooth needle shoulder for seamless passage through the dilator. Smooth needle surface to prevent debris during insertion. Stainless steel needle hub, copper-free, for enhanced surgical safety. Stable Support: […]

Blog

6 pages
  1. Clinical Applications Of Drug Eluting Balloon-Part 1/2020/05/30/clinical-applications

    Drug-eluting stents can inhibit the proliferation of smooth muscle cells in the vessel wall, balloon catheter and significantly reduce the restenosis rate after intervention compared with ordinary balloons and bare metal stents, but such stents also inhibit vascular endothelial repair, causing delayed or incomplete endothelialization, which is easy to induce Late thrombosis in the stent. […]

  2. Clinical Applications Of Drug Eluting Balloon-Part 2/2020/06/13/clinical-applications-of-drug-eluting-balloon-part-2

    It does not require multi-polymers, does not induce advanced thrombosis, and may reduce the time of double antiplatelet therapy. Therefore, it is difficult for DES treatment, such as small blood vessels, anatomically curved blood vessels, diffuse long lesions, bifurcation lesions, and oral lesions，DEB is an alternative method. DEB still has some shortcomings: it cannot solve […]

  3. Current status of interventional treatment of coronary heart disease in China/2020/05/13/interventional-treatment-of-coronary-heart-disease-in-china

    In 1977, the first percutaneous transluminal coronary angioplasty (PTCA) opened the era of modern interventional cardiology, and interventional cardiology changed from diagnosis to treatment. After 30 years of development since the first case of coronary stent implantation in 1986, percutaneous coronary intervention (PCI) has become the most popular coronary intervention in the world balloon catheter. […]

  4. Knowledge Center/knowledge-center

Press

6 pages
  1. 2021 Peking University Vascular Forum concluded perfectly!/2021/10/27/2021-peking-university-vascular-forum-concluded-perfectly

    The 2021 Peking University Vascular Forum will be held in Beijing, Capital of China, from October 14 to 16, 2021. Peking University Vascular Forum is one of the largest, most influential and most educational brand conferences in the field of vascular surgery and vascular intervention in China. With the Octoparms® umbrella-shaped vena cava filter and […]

  2. A roadshow of "Most Growing High-tech Enterprise" contest/2019/04/16/a-roadshow-of-most-growing-high-tech-enterprise-contest

    On September 28th, 2017, Dr. Hu represented Kossel Medtech make a roadshow in the “Most High-tech Hi-tech Enterprise” contest.

  3. An honorary title of high-tech enterprise/2019/04/16/an-honorary-title-of-high-tech-enterprise

    Warmly celebrate Kossel Medtech to be awarded the honorary title of high-tech enterprise in 2016!

  4. Kossel Medtech, School and Enterprise jointly set up "Heart Award"/2021/09/28/heart-award

    Who is Kossel Medtech? Kossel is a manufacture of PTCA BALLOON DILATATION CATHETER and PTA BALLOON CATHETER.

About

1 page
  1. About Us/about-us

Contact

3 pages
  1. Contact Us/contact-us

    CONTACT US KOSSEL MEDTECH (SUZHOU) CO., LTD. We are always ready to help you. There are many ways to contact us. You may drop us a line, give us a call or send an email, choose what suits you most. Tel: +86-512-8717-4080 Fax: +86-512-8717-4081 E-mail: nicole.ma@kosselmed.com WhatsApp：+86 131 4777 1518 Website: www.kossel-medical.com Add: Building 6, […]

  2. Contract Service/service

    Kossel Medtech has the strong technical team and complete production line to develop and produce balloon catheters.

  3. FAQ/faq

    FAQ What types of products do you offer? We offer wide range of vascular interventional and implantable products, including PTCA, NC PTCA, CTO, PTA, inflation device, radial artery tourniquet, diagnostic electrophysiology catheter, cardiac ablation catheter, and vena cava filter. Where is your market? We are a worldwide supplier. Our products have been used in more […]

Homepage

1 page
  1. Homepage/

    Kossel focuses on R&D, manufacturing and distributing of cardiovascular interventional medical devices, including balloon catheter, coronary stent delivery system, electrophysiology series products.

Privacy

1 page
  1. Privacy Policy/privacy-policy

    Privacy Policy This privacy policy describes how we handle your personal information. By using wkossel-medical.com(the “Site”) you consent to the storage, processing, transfer and disclosure of your personal information as described in this privacy policy.   Collection You may browse this Site without providing any personal information about yourself. However, to receive notifications, updates or […]

Coverage

5 items
  1. Joining Forces for Mutual Success — Kossel Medtech and FuseMedTech Announce Strategic Partnershipkossel-medical.com/2026/09/29/joining-forces-for-mutual-success-kossel-medtech-and-fusemedtech-announce-strategic-partnership/

    Kossel Medtech and FuseMedTech announce a strategic partnership. The announcement highlights the FuseVive® Pulmonary Artery Thrombectomy System as the anchor of a product portfolio that addresses peripheral vascular embolism, peripheral thrombus removal, and hepatic interventional procedures.

    Sep 2026 · Kossel MedtechNews article

  2. Deepening European Presence and Accelerating Global Layout | Kossel at CIRSE 2026kossel-medical.com/2026/09/23/deepening-european-presence-and-accelerating-global-layout-kossel-at-cirse-2026/

    Kossel made a significant appearance at this year’s CIRSE congress, showcasing its CE-certified peripheral interventional product portfolio. The displayed products were Falspeed® PTA Balloon Dilatation Catheter, Falexpand® HP PTA Balloon Dilatation Catheter, Tanghulu® PTA Balloon Dilatation Catheter, and Giranel® Guiding Sheath Set.

    Sep 2026 · Kossel MedtechNews article

  3. Press Release: Kossel Obtains Multi‑country Registrations in ASEAN, Achieving Key Breakthrough for Globalizationkossel-medical.com/2026/09/23/press-release-kossel-obtains-multi-country-registrations-in-asean-achieving-key-breakthrough-for-globalization/

    Kossel says four medical devices have received registration from Indonesia’s Ministry of Health, allowing commercial sale in the country. The registrations cover the Falspeed® PTA Balloon Dilatation Catheter, Sabelly® NC PTA Balloon Dilatation Catheter, Falexpand® HP PTA Balloon Dilatation Catheter, and MiSatin® Hydrophilic Guidewire.

    Sep 2026 · Kossel MedtechNews article

  4. Kossel Medtech Expands Global-Oriented Ecosystem: Strategic Partnership with Silvan Medical to Accelerate Global Commercialization of Vascular Closure Systemkossel-medical.com/2026/09/01/kossel-medtech-expands-global-oriented-ecosystem/

    Kossel Medtech (Suzhou) has a strategic cooperation agreement with Suzhou Silvan Medical concerning the Clothoid Vascular Closure System. The agreement gives Kossel exclusive responsibility for the system’s overseas commercial rollout, with the partnership described as accelerating global commercialization.

    Sep 2026 · Kossel MedtechNews article